This company listing is no longer active
ALPHE Stock Overview
Pherecydes Pharma Société anonyme develops antibacterial treatments based on the use of bacteriophage viruses or phages. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Pherecydes Pharma Société anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.00 |
| 52 Week High | €4.36 |
| 52 Week Low | €1.72 |
| Beta | 0.99 |
| 1 Month Change | -0.99% |
| 3 Month Change | -18.70% |
| 1 Year Change | -53.60% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -79.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALPHE | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | 2.6% | -0.9% | -1.8% |
| 1Y | -53.6% | -28.0% | -4.9% |
Return vs Industry: ALPHE underperformed the French Biotechs industry which returned -25.4% over the past year.
Return vs Market: ALPHE underperformed the French Market which returned 18.9% over the past year.
Price Volatility
| ALPHE volatility | |
|---|---|
| ALPHE Average Weekly Movement | 6.0% |
| Biotechs Industry Average Movement | 7.1% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.5% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALPHE's share price has been volatile over the past 3 months.
Volatility Over Time: ALPHE's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 29 | Thibaut Fayet | www.pherecydes-pharma.com |
Pherecydes Pharma Société anonyme develops antibacterial treatments based on the use of bacteriophage viruses or phages. It develops a portfolio of therapeutics, such as anti-staphylococcus aureus for the treatment of bone/joint and diabetic foot ulcer infections; anti-pseudomonas aeruginosa, a phage therapy treatment for respiratory tract infections; and anti-escherichia coli for the treatment of respiratory tract infections. The company was founded in 2006 and is headquartered in Romainville, France.
Pherecydes Pharma Société anonyme Fundamentals Summary
| ALPHE fundamental statistics | |
|---|---|
| Market cap | €14.44m |
| Earnings (TTM) | -€4.85m |
| Revenue (TTM) | €3.16m |
4.6x
P/S Ratio-3.0x
P/E RatioIs ALPHE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALPHE income statement (TTM) | |
|---|---|
| Revenue | €3.16m |
| Cost of Revenue | €5.42m |
| Gross Profit | -€2.27m |
| Other Expenses | €2.59m |
| Earnings | -€4.85m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
Sep 19, 2023
| Earnings per share (EPS) | -0.67 |
| Gross Margin | -71.91% |
| Net Profit Margin | -153.85% |
| Debt/Equity Ratio | 33.7% |
How did ALPHE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/06/26 12:06 |
| End of Day Share Price | 2023/06/26 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pherecydes Pharma Société anonyme is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Arnaud Despre | Portzamparc BNP Paribas |
| Mohamed Kaabouni | Portzamparc BNP Paribas |
| Claire Deray | TPICAP Midcap |